fMRI Guided TMS Enhancement of Associative Memory Networks

NYU Langone Health

Status

Terminated

Conditions

Epilepsy

Treatments

Diagnostic Test: MagStim RapidStim2

Study type

Interventional

Funder types

Other

Identifiers

NCT02749422

15-00732

Details and patient eligibility

About

This is a randomized, single-blinded, controlled phase 1 study to demonstrate feasibility and explore the neurophysiologic and clinical effects of repetitive transcranial magnetic stimulation (TMS) interventions in epilepsy patients and healthy controls. The inclusion of a control group will be used to see whether epilepsy patients, who suffer from a higher degree of comorbid memory difficulty presumably from entorhinal-hippocampal dysfunction, can benefit from a TMS intervention can benefit as much as a healthy matched population. Investigators will also be looking at functional connectivity between the hippocampus and cortical regions

Enrollment

8 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Fluent in English
Right-handed
Score at least 26 out of 30 on the Montreal Cognitive Assessment (MOCA). Healthy subjects will be matched to age, handedness, and education compared to epilepsy subjects.
Must be able to provide informed consent.

Exclusion criteria

Any history of a neurological disorder
Chronic or progressive medical condition
Any history of severe traumatic brain injury or skull defect
Metal or devices in the head, including neurostimulators of metal foreign bodies
Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
Any other ferromagnetic substance in the body (including tattoos, dental prosthetics, etc).
Taking a medication which may lower the seizure threshold within the 4 weeks prior to the start of the study, including use of neuroleptic (esp. clozapine), antibiotic (penicillin, cephalosporins), and bronchodilating medications.
Pregnancy